Summit Therapeutics PLC (LSE:SUMM) - Share price - Overview

Stock Report

Summit Therapeutics PLC SUMM

Last Price
GBX34.50

Day Change
-1.50|-4.17%

As of 19/07/2018
17:07:50 BST | GBX
Minimum 15 Minutes Delay.

Last Close36.00p
Day Range34.10 - 37.00
Mkt Cap29.52Mil
52-Wk Range31.00 - 269.70
Yield %-
ISINGB00BN40HZ01
Volume181,096
P/E-3.15
P/S0.01
P/CF-0.02

Share Price

Total Returns 18/07/2018

 Chg (%)  
More ...
Summit Therapeutics PLC-81.54 
FTSE 100 TR GBP1.18
 
Financials
201620172018
More ...
Income Statement
Turnover0.002.3025.42
Operating Profit-20.35-24.32-10.80
Net Profit-20.14-21.37-7.13
Reported EPS-34.00-35.00-11.00
Balance Sheet
Current Assets20.8433.3435.89
Non Current Assets4.224.2518.07
Total Assets25.0637.5953.96
Current Liabilities3.2110.9018.94
Total Liabilities8.9841.0844.09
Total Equity16.08-3.499.88
Cash Flow
Operating Cash Flow-18.589.14-18.06
Net Change in Cash4.9212.47-6.03
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
16/07/2018PurchaseDr. Frank Murdoch Armstrong39.5025,0009,875.00
13/07/2018PurchaseMr. Glyn Owain Edwards MBE38.00150,00057,000.00
23/04/2018Exercise of OptionDr. Barry John Price65.0013,9819,088.00
23/04/2018Exercise of OptionDr. Barry John Price126.0017,50022,050.00

Company Profile

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE AIM All-Share

Next Event 31/08/2018

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-30.83
Op Mrgn-0.43
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorMr. David M. Wurzer
Non-Executive DirectorMs. Valerie L. Andrews
Non-Executive DirectorDr. Barry John Price
Executive Director, Chief Executive OfficerMr. Glyn Owain Edwards MBE
Non-Executive DirectorProf Stephen Graham Davies
Non-Executive Director, ChairmanDr. Frank Murdoch Armstrong
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.